Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 10.79 Million USD | 41.77% |
| 2022 | 7.61 Million USD | 150.77% |
| 2021 | -14.99 Million USD | -989.83% |
| 2020 | -1.37 Million USD | 74.58% |
| 2019 | -5.41 Million CAD | -23.22% |
| 2018 | -4.39 Million CAD | -101.76% |
| 2017 | -2.17 Million CAD | -267.72% |
| 2016 | -592.04 Thousand CAD | 42.64% |
| 2015 | -1.03 Million CAD | 14.75% |
| 2014 | -1.21 Million CAD | 75.2% |
| 2013 | -4.88 Million CAD | -3164.06% |
| 2012 | -149.56 Thousand CAD | -109759.78% |
| 2011 | -136.14 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.97 Million USD | 377.64% |
| 2023 Q4 | 832 Thousand USD | -46.94% |
| 2023 Q3 | 1.56 Million USD | -55.88% |
| 2023 Q2 | 3.55 Million USD | -26.57% |
| 2023 Q1 | 4.84 Million USD | 77.03% |
| 2023 FY | 10.79 Million USD | 41.77% |
| 2022 Q1 | 33 Thousand USD | 101.32% |
| 2022 Q2 | 1.94 Million USD | 5800.0% |
| 2022 Q3 | 2.9 Million USD | 48.95% |
| 2022 Q4 | 2.73 Million USD | -5.72% |
| 2022 FY | 7.61 Million USD | 150.77% |
| 2021 FY | -14.99 Million USD | -989.83% |
| 2021 Q2 | -4.99 Million USD | 30.31% |
| 2021 Q3 | -339 Thousand USD | 93.21% |
| 2021 Q1 | -7.16 Million USD | -52.65% |
| 2021 Q4 | -2.5 Million USD | -638.64% |
| 2020 Q3 | 1.56 Million CAD | 234.31% |
| 2020 Q4 | -4.69 Million USD | -399.13% |
| 2020 Q2 | 469.16 Thousand CAD | -59.95% |
| 2020 Q1 | 1.17 Million CAD | 216.44% |
| 2020 FY | -1.37 Million USD | 74.58% |
| 2019 Q1 | -873.81 Thousand CAD | 45.11% |
| 2019 Q3 | -2.53 Million CAD | -159.9% |
| 2019 Q2 | -976.73 Thousand CAD | -11.78% |
| 2019 FY | -5.41 Million CAD | -23.22% |
| 2019 Q4 | -1 Million CAD | 60.37% |
| 2018 Q1 | -320.97 Thousand CAD | 64.32% |
| 2018 Q4 | -1.59 Million CAD | -2684.62% |
| 2018 FY | -4.39 Million CAD | -101.76% |
| 2018 Q3 | -57.17 Thousand CAD | 97.86% |
| 2018 Q2 | -2.67 Million CAD | -732.88% |
| 2017 Q1 | -644.15 Thousand CAD | 22.97% |
| 2017 Q3 | -569.84 Thousand CAD | -1254.84% |
| 2017 Q4 | -899.5 Thousand CAD | -57.85% |
| 2017 FY | -2.17 Million CAD | -267.72% |
| 2017 Q2 | -42.06 Thousand CAD | 93.47% |
| 2016 Q2 | -441.23 Thousand CAD | 66.26% |
| 2016 FY | -592.04 Thousand CAD | 42.64% |
| 2016 Q1 | -1.3 Million CAD | -199.83% |
| 2016 Q4 | -836.19 Thousand CAD | -43.45% |
| 2016 Q3 | -582.92 Thousand CAD | -32.11% |
| 2015 FY | -1.03 Million CAD | 14.75% |
| 2015 Q4 | 1.3 Million CAD | 266.01% |
| 2015 Q3 | -789.03 Thousand CAD | -39.24% |
| 2015 Q2 | -566.67 Thousand CAD | 49.55% |
| 2015 Q1 | -1.12 Million CAD | -174.74% |
| 2014 Q1 | -778.83 Thousand CAD | 0.0% |
| 2014 FY | -1.21 Million CAD | 75.2% |
| 2014 Q4 | 1.5 Million CAD | 255.01% |
| 2014 Q2 | -1.06 Million CAD | -37.32% |
| 2014 Q3 | -969.5 Thousand CAD | 9.35% |
| 2013 Q3 | -49.19 Thousand CAD | -198.57% |
| 2013 FY | -4.88 Million CAD | -3164.06% |
| 2013 Q1 | -1995.89 CAD | 79.78% |
| 2013 Q2 | -16.47 Thousand CAD | -725.48% |
| 2012 Q4 | -9870.76 CAD | 98.24% |
| 2012 Q1 | -29.75 Thousand CAD | 68.51% |
| 2012 Q3 | -561.71 Thousand CAD | -23466.54% |
| 2012 FY | -149.56 Thousand CAD | -109759.78% |
| 2012 Q2 | -2383.54 CAD | 91.99% |
| 2011 Q4 | -94.47 Thousand CAD | 0.0% |
| 2011 FY | -136.14 CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -46.45 Million CAD | 123.236% |
| Avicanna Inc. | -7.93 Million CAD | 236.064% |
| Avant Brands Inc. | -1.45 Million CAD | 843.901% |
| Cardiol Therapeutics Inc. | -29.78 Million CAD | 136.239% |
| Crescita Therapeutics Inc. | -1.95 Million CAD | 651.84% |
| Knight Therapeutics Inc. | -2.89 Million CAD | 473.495% |
| MediPharm Labs Corp. | -18.25 Million CAD | 159.139% |
| OrganiGram Holdings Inc. | -242.73 Million CAD | 104.447% |
| Canopy Growth Corporation | -228.71 Million CAD | 104.719% |
| Willow Biosciences Inc. | -13.18 Million CAD | 181.884% |
| Auxly Cannabis Group Inc. | -19 Million CAD | 156.796% |